Novartis Kymriah receives EC approval for lymphoma treatment
Approval for Kymriah follows a positive CHMP opinion and is applicable to all 27 EU member states
Read More
Tag: Kymriah
Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial
Phase III study was investigating treatment for B-cell non-Hodgkin lymphoma
Read More
Novartis’ CAR-T therapy Kymriah hits endpoint in follicular lymphoma trial
Company expect to file regulatory submissions in 2021
Read More
Kymriah leads latest round of SMC decisions
MSD’s Keytruda, Pfizer’s Visimpro, AstraZeneca’s Forxiga and Shionogi’s Senshio were also accepted.
Read More
SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma
Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.
Read More
Yescarta rejected among other SMC decisions
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Read More
Kymriah gets NICE approval for DLBCL
The National Institute for Health and Care Excellence (NICE) has approved Novartis’ chimeric antigen receptor T-cell (CAR T-cell) therapy Kymriah for treatment of adults with diffuse large B-cell lymphoma (DLBCL).
Read More
Novartis’ Kymriah shows ‘strong efficacy’, ‘durable response’ in new analysis
Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients.
Read More
First children set to receive Novartis’ Kymriah
The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer – will start treatment at Great Ormond Street Hospital in London this week, NHS England has announced.
Read More
NICE issues final draft guidelines for Novartis’ Kymriah
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
Read More
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma
The National Institute for Health and Care Excellence has turned down NHS funding for use of Novartis’ CAR-T therapy Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Read More
NHS England strikes deal with Novartis on Kymriah
Hospitals are gearing up to offer Novartis’ ground-breaking CAR-T therapy Kymriah to children with advanced leukaemia, after the drugmaker reached a deal with NHS England over its provision.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
